Stocks eventually converge into their fair values, divergence (trading lower for a while compared to the fair value) is perfectly normal in little biotechs' world. Apri has a good business case to justify much higher pps NOW. Let hedge scums play their games, they can't push or keep Apri's pps at lower levels forever. I still believe that we should have an easy double from current levels in pretty near term.
News 
Market Data 
Discover 
